BC Extra | Apr 30, 2018
Company News

Allergan drops RORgammaT inhibitor for psoriasis

Allergan plc (NYSE:AGN) terminated development of VTP-43742 to treat psoriasis due to safety signals in a Phase II study, EVP and Chief R&D Officer C. David Nicholson said on the company's 1Q18 earnings call. The...
BC Extra | Nov 17, 2017
Company News

Management tracks: Scynexis, Context

Infectious disease company Scynexis Inc. (NASDAQ:SCYX) hired Scott Sukenick as general counsel. He was an attorney at Cooley. Cancer company Context Therapeutics (Philadelphia, Pa.) named Scott Applebaum president and Richard Morris EVP and CFO. Applebaum...
BC Week In Review | Oct 20, 2017
Company News

Syndax licenses menin-MLL inhibitors from Allergan

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) obtained an exclusive, worldwide license to inhibitors of the menin-MLL fusion oncogene from the Vitae Pharmaceuticals Inc. subsidiary of Allergan plc (NYSE:AGN). Syndax plans to begin clinical trials in 2019 of...
BC Extra | Oct 17, 2017
Company News

Syndax in menin-MLL deal with Allergan

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) obtained an exclusive, worldwide license to inhibitors of the menin-MLL fusion oncogene from the Vitae Pharmaceuticals Inc. subsidiary of Allergan plc (NYSE:AGN). Syndax plans to begin clinical trials in 2019 of...
BC Extra | Oct 11, 2017
Company News

Zafgen names Hatfield CEO

Metabolic disease company Zafgen Inc. (NASDAQ:ZFGN) hired Jeffrey Hatfield as CEO. He replaces Thomas Hughes, who will remain president and become CSO. Hatfield was CEO of Vitae Pharmaceuticals Inc. , which Allergan plc (NYSE:AGN) acquired in...
BC Extra | Jan 11, 2017
Clinical News

Allergan discloses Phase II miss in LXR program

Allergan plc (NYSE:AGN) said VTP-38543 did not show proof of concept in a Phase II trial to treat atopic dermatitis. Allergan acquired the liver X receptor beta ( NR1H2 ; LXR-b) agonist via its $639 million...
BC Week In Review | Nov 11, 2016
Clinical News

VTP-38543: Ph I/II data

Allergan said that "target engagement was not satisfactorily achieved" in a Phase I/II trial evaluating VTP-38543 in patients with mild to moderate atopic dermatitis. The company said it plans to re-evaluate the concentration and formulation...
BC Week In Review | Oct 31, 2016
Company News

Vitae, Allergan deal

Allergan completed its acquisition of Vitae for $21 per share in cash in a deal the companies say values Vitae at about $639 million (see BioCentury, Sept. 16). Vitae Pharmaceuticals Inc. , Fort Washington, Pa.  Allergan...
BioCentury | Oct 10, 2016
Finance

M&Allergan

Even after a two-month stretch that has seen Allergan plc (NYSE:AGN) acquire five biotechs and in-license a pharma asset, the company's gas tank is still nearly full. Allergan's bank account swelled to nearly $37 billion...
BC Week In Review | Sep 19, 2016
Company News

Vitae, Allergan deal

Allergan will acquire Vitae for $21 per share in cash in a deal the companies say values Vitae at about $639 million. The price is a 159% premium to Vitae’s close of $8.10 on Sept....
Items per page:
1 - 10 of 112
BC Extra | Apr 30, 2018
Company News

Allergan drops RORgammaT inhibitor for psoriasis

Allergan plc (NYSE:AGN) terminated development of VTP-43742 to treat psoriasis due to safety signals in a Phase II study, EVP and Chief R&D Officer C. David Nicholson said on the company's 1Q18 earnings call. The...
BC Extra | Nov 17, 2017
Company News

Management tracks: Scynexis, Context

Infectious disease company Scynexis Inc. (NASDAQ:SCYX) hired Scott Sukenick as general counsel. He was an attorney at Cooley. Cancer company Context Therapeutics (Philadelphia, Pa.) named Scott Applebaum president and Richard Morris EVP and CFO. Applebaum...
BC Week In Review | Oct 20, 2017
Company News

Syndax licenses menin-MLL inhibitors from Allergan

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) obtained an exclusive, worldwide license to inhibitors of the menin-MLL fusion oncogene from the Vitae Pharmaceuticals Inc. subsidiary of Allergan plc (NYSE:AGN). Syndax plans to begin clinical trials in 2019 of...
BC Extra | Oct 17, 2017
Company News

Syndax in menin-MLL deal with Allergan

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) obtained an exclusive, worldwide license to inhibitors of the menin-MLL fusion oncogene from the Vitae Pharmaceuticals Inc. subsidiary of Allergan plc (NYSE:AGN). Syndax plans to begin clinical trials in 2019 of...
BC Extra | Oct 11, 2017
Company News

Zafgen names Hatfield CEO

Metabolic disease company Zafgen Inc. (NASDAQ:ZFGN) hired Jeffrey Hatfield as CEO. He replaces Thomas Hughes, who will remain president and become CSO. Hatfield was CEO of Vitae Pharmaceuticals Inc. , which Allergan plc (NYSE:AGN) acquired in...
BC Extra | Jan 11, 2017
Clinical News

Allergan discloses Phase II miss in LXR program

Allergan plc (NYSE:AGN) said VTP-38543 did not show proof of concept in a Phase II trial to treat atopic dermatitis. Allergan acquired the liver X receptor beta ( NR1H2 ; LXR-b) agonist via its $639 million...
BC Week In Review | Nov 11, 2016
Clinical News

VTP-38543: Ph I/II data

Allergan said that "target engagement was not satisfactorily achieved" in a Phase I/II trial evaluating VTP-38543 in patients with mild to moderate atopic dermatitis. The company said it plans to re-evaluate the concentration and formulation...
BC Week In Review | Oct 31, 2016
Company News

Vitae, Allergan deal

Allergan completed its acquisition of Vitae for $21 per share in cash in a deal the companies say values Vitae at about $639 million (see BioCentury, Sept. 16). Vitae Pharmaceuticals Inc. , Fort Washington, Pa.  Allergan...
BioCentury | Oct 10, 2016
Finance

M&Allergan

Even after a two-month stretch that has seen Allergan plc (NYSE:AGN) acquire five biotechs and in-license a pharma asset, the company's gas tank is still nearly full. Allergan's bank account swelled to nearly $37 billion...
BC Week In Review | Sep 19, 2016
Company News

Vitae, Allergan deal

Allergan will acquire Vitae for $21 per share in cash in a deal the companies say values Vitae at about $639 million. The price is a 159% premium to Vitae’s close of $8.10 on Sept....
Items per page:
1 - 10 of 112